“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”
In Brief: Override Failure Would Leave Cancer Program With No Money or New Projects Of Any Kind
NCI Budget for FY 1977 Would Halt New Research
Congressman Obey Attacks NCI for Not Supporting Basic Research
Nutrition RFPs Will Really Be Grants, Gori Says
Cyclamate Committee Finds No Proof Of Carcinogenicity
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - Alec Kimmelman announced as next CEO and Dean of NYU Langone Health